sprite-preloader
Anzeige
Mehr »
Sonntag, 19.11.2017 Börsentäglich über 12.000 News von 570 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A0EAT9 ISIN: BE0003818359 Ticker-Symbol: GXE 
Aktie:
Branche
Biotechnologie
Aktienmarkt
BEL-20
AEX
1-Jahres-Chart
GALAPAGOS NV Chart 1 Jahr
1-Woche-Intraday-Chart
GALAPAGOS NV 1-Woche-Intraday-Chart
RealtimeGeldBriefZeit
76,94
77,56
18.11.
77,12
77,43
17.11.
21.04.2017 | 22:04
(12 Leser)
Schrift ändern:
(0 Bewertungen)

GlobeNewswire (Europe)·Mehr Nachrichten von GlobeNewswire (Europe)

Mechelen, Belgium; 21 April 2017, 22.01 CET; regulated information - Galapagos NV (Euronext: GLPG; Nasdaq: GLPG) announces a share capital increase as a result of a public offering of American Depositary Shares.

In accordance with Belgian transparency legislation[1] (#_ftn1), Galapagos notes that its total share capital currently amounts to €274,854,440.18; the total number of securities conferring voting rights is 50,815,648, which is also the total number of voting rights (the "denominator"), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights is 3,369,337, which equals the total number of voting rights that may result from the exercise of these warrants. Galapagos does not have any convertible bonds or shares without voting rights outstanding.

About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises Phase 3, 2, 1, pre-clinical and discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 510 employees, operating from its Mechelen, Belgium headquarters and facilities in The  Netherlands, France, and Croatia.

CONTACT

 

Investors:
 

Media:
Elizabeth Goodwin Evelyn Fox
VP IR & Corporate
Communications
+1 781 460 1784
Director Communications

+31 6 53 591 999

communications@glpg.com
 

Paul van der Horst
Director IR & Business
Development
+31 6 53 725 199
 

 
ir@glpg.com  

Forward-looking statements
This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.



[1] (#_ftnref1) Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market.


GLPG announces capital increase (http://hugin.info/133350/R/2097796/794375.pdf)



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire


© 2017 GlobeNewswire (Europe)